Highlights {#S1}
==========

1.  Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder.

2.  P2X7R is upregulated in AD.

3.  P2X7R is involved in microglial function, synaptopathy, oxidative stress, and amyloidogenic APP processing.

4.  Induced pluripotent stem cell (iPSC) is a promising new therapeutic approach in AD.

Alzheimer's Disease {#S2}
===================

Alzheimer's disease (AD) is a devastating neurodegenerative disorder currently affecting more than 47 million people around the world, expecting to reach more than 131 million by 2050. Typical AD onset is after 65 years old, although in less than 5% of cases, onset may be earlier ([@B7]). Approximately between 1 and 3% of AD patients present autosomal dominant form of AD, denominated early familiar AD (eFAD) ([@B140]). This form is characterized by mutations in both amyloid-β (Aβ) precursor protein (APP) and enzymes related in its processing, like presenilin-1 and presenilin-2 (PSEN1 and PSEN2) ([@B140]; [@B103]).

Symptoms associated to AD follow a progressive course, starting with an impairment in learning and memory, proceeding to later detriments in complex attention, executive functions, language, visuospatial compartment, praxis, gnosis, behavior, and/or social compartment ([@B114]). At neuropathological level, postmortem brains from AD patients show atrophy of frontotemporal cortex and hippocampus caused by neuronal loss, neuroinflammation, loss of synapses, and oxidative stress. Typical hallmarks of AD are extracellular senile plaques and intracellular neurofibrillary tangles (NFTs) ([@B60]; [@B154]; [@B9]; [@B137]). Senile plaques are formed by β-amyloid Aβ peptides, generated by the sequential proteolysis of APP by β-secretase 1 (BACE1) and γ-secretase (PSEN1 and 2, Nicastrin, and APH-1) ([@B154]). NFTs are assembled by abnormal accumulation of hyperphosphorylated tau protein \[microtubule associated protein tau (MAPT)\] ([@B9]). Aβ peptide and phosphorylated Tau protein, primary criteria for AD diagnosis, are considered the main toxic species involved in AD ([@B106]). Indeed, detection of Aβ and tau deposition in cerebrospinal fluid (CSF) or positron emission tomography (PET) imaging presents now an antemortem AD neuropathology diagnosis ([@B18]; [@B108]).

Current Therapeutic Strategies in AD {#S2.SS1}
------------------------------------

There are only four commercial palliative-treatments available for symptomatic AD patients: three acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, a non-competitive NMDA receptors modulator ([@B106]). Despite all efforts made, there is no effective treatment available for symptomatic AD patients. Over the last decade, numerous clinical trials have been carried out to avoid the amyloid toxicity associated with AD. One of those was focused on developing specific monoclonal antibodies against Aβ, both soluble and fibrillar forms ([@B46]; [@B149]; [@B156]) or try to induce an active immunization. Other strategies have attempted to reduce brain Aβ burden designing new potent secretase inhibitors, both against γ-secretase or BACE1 inhibitors ([@B48], [@B49]; [@B74]; [@B107]). Another trial used anti-inflammatory drugs to avoid Aβ-induced neuroinflammation, focusing on the inhibition of the cyclooxygenase enzyme ([@B2]; [@B36]). Since some studies have shown increased levels of cholesterol promoting the production of Aβ, other clinical trials used statins likes hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors as cholesterol-lowering agents ([@B22]; [@B53]). Regarding Tau-based clinical trials, the followed strategies have been focused on reducing its intracellular phosphorylation rate ([@B45]), avoiding its aggregation ([@B185], [@B186]), or allowing its removal using immunotherapy approaches. Tau immunotherapy is based on both active and passive immunization approaches. Active immunization must be handled carefully, avoiding the pathogenic activation of the immune system, in particular T-cells, that could lead to aseptic meningo-/encephalitis endangering patient safety. In contrast, passive immunotherapy provides the advantage of control over antibodies' binding properties and their blood concentrations ([@B178]). So far, nine ongoing immunotherapy studies are being reported ([@B6]), two of which are active immunotherapies: AADvac1 ([@B130]) and ACI-35 ([@B170]); and seven passive immunotherapies: R07105705 ([@B100]), Zagotenemab (LY3303560) ([@B3]), BIIB076 ([@B33]), ABBV-8E12 (C2N 8E12) ([@B187]), Gosuranemab (BIIB092) ([@B17]), UCB0107 ([@B5]), and JNJ-63733657 ([@B5]). While there are several clinical trials ongoing ([@B106]), complementary approaches targeting alternative pathways still need to be explored.

Over the last two decades, several pieces of evidence suggest that some elements of purinergic signaling, in particular P2X7R, might contribute to AD pathology ([@B135]; [@B116]; [@B146]; [@B151]; [@B38]; [@B43]; [@B152]; [@B109]; [@B110]). The first observation of the possible involvement of P2X7R in AD was based on the upregulation of this receptor in microglial cells surrounding senile plaques both in human AD patients and animal models mimicking AD ([@B135]; [@B116]; [@B146]). Genetic evidence also provided an association between P2X7R and AD, finding a negative correlation among P2X7R 489C\>T polymorphism and AD ([@B152]). Later studies supplied additional proofs supporting the involvement of P2X7R in the amyloidogenic APP processing ([@B38]; [@B43]), synaptic dysfunction ([@B98]; [@B148], [@B147]; [@B63]), oxidative stress ([@B135]; [@B98]; [@B191]), and neuroinflammation ([@B88]; [@B151]; [@B27]; [@B109]; [@B110]), associated to AD ([Figure 1](#F1){ref-type="fig"}). Supporting the potential therapeutic role of P2X7R, others groups demonstrated that its pharmacological blockade or genetic depletion leads to a significant improvement both symptomatology and neuropathology in AD animal models ([@B146]; [@B43]; [@B26]; [@B109]). In this review, we are going to examine the different findings supporting a critical role of P2X7R in the regulation of molecular mechanisms underlying AD.

![Schematic illustration summarizing the pieces of evidence accumulated over the past years indicating that P2X7R plays a central role in the different physiopathological processes associated with Alzheimer's disease. The outer circular arrows illustrate a chain of interconnected and mutually influenced pathological processes associated with AD. Inner arrows represent the relationships found between P2X7R and these pathological processes, summarizing the studies discussed in the present review. Briefly, P2X7R modulates amyloid APP processing, and it is postulated as a neuroinflammation triggering factor. Upregulated P2X7R expression in AD patients and different AD and neuroinflammation mouse models give it a key role in disease progression. Besides, P2X7R also contributes to neuronal loss and synaptic alterations, oxidative stress; inflammasome assembling; and altered microglial function, being all of them processes contributing to AD progression, as described in the present review.](fnmol-13-00094-g001){#F1}

P2X7R {#S3}
=====

P2X receptors are plasma membrane ligand-gated ion channels, whose activation causes a selective influx of small cations (Na^+^, Ca^2+^) and K^+^ efflux from cells ([@B128]; [@B70]; [@B150]). Similar to other members of P2X family, P2X7 subunit has two transmembrane domains linked by a large extracellular domain ([@B128]). These subunits present a dolphin-shaped structure with the transmembrane helices and the extracellular region similar to the tail and the body, respectively ([@B112]). Among all P2X receptors, P2X7 is the only one found as a homotrimer in physiological models. Human P2X7R protein is a 595 amino acid protein encoded by the *P2RX7* gene located on chromosome 12 (12q24.31 locus) spanning 53,733 bases ([@B126]). Alternative splicing takes place during gene's transcription and may give rise to at least 11 different splice variants of P2X7R, described to date ([@B143]; [@B24]; [@B159], [@B160]; [@B54]; [@B1]; [@B161]). Specific features of full length P2X7 protein include a large C-terminal domain ([@B177]); low sensitivity to its native ligand (ATP) and sensitive to extracellular divalent cations ([@B166]). Different intracellular mediators have been associated with P2X7R activation such as calcium calmodulin kinases II ([@B44]), nuclear factor kappa-light-chain-enhancer (NFκB) ([@B55]), ROS/NOS formation ([@B75]), glycogen synthase kinase-3 (GSK3) ([@B44]), phospholipase D ([@B78]), inflammasome "NACHT, LRR, and PYD domains-containing protein 3" (NLRP3) ([@B57]). However, sustained activation of P2X7R by high ATP concentrations may induce apoptosis or necrosis in some cellular lineages ([@B177]; [@B39]).

Although its specific distribution in the CNS remains debated ([@B121]; [@B79]), P2X7R expression has been reported in almost all cellular lineages making up the brain tissue, including astrocytes, microglia, oligodendrocytes, and neurons ([@B111]; [@B121]). Interestingly, P2X7R has also been related to several physiological events including neuronal differentiation ([@B118]; [@B171]; [@B62]; [@B58]), axonal growth and branching ([@B44]), presynaptic regulation and neurotransmitter release ([@B163]; [@B120]; [@B101]), microglial activation, migration, and proliferation ([@B151]; [@B145]; [@B110]), glial and microglial phagocytosis ([@B127]; [@B65]; [@B110]).

Upregulation of P2X7R in Alzheimer's Disease {#S3.SS1}
--------------------------------------------

One of the initial pieces of evidence suggesting a possible involvement of P2X7R in AD was the increased P2X7R expression found in microglial cells surrounding amyloid plaques both in AD patients and different AD mouse models ([@B135]; [@B116]). Later studies using two different mouse models of AD based on the transgenic expression of human APP (APP/PS1 mice and J20 mice, thoroughly described below) confirmed that P2X7R upregulation in activated microglial was parallel with AD progression ([@B98]; [@B110]). Another study showed that 9-months-old P301S tau mice, overexpressing mutant human protein tau (MAPT P301S) driven by the mouse prion protein (*Prnp*) promoter ([@B189]), show a higher cerebral binding of a radiotracer for P2X7R, \[^123^I\]TZ26019, than their corresponding WT control mice. Subsequent analysis revealed that P2X7R was mainly found in hippocampal astrocytes in P301S mice ([@B87]). However, no robust data about the molecular mechanism causing the glial P2X7R upregulation were provided in these studies. Although astroglial activation is a histopathological mark associated with tau-induced toxicity, including AD, little is know about how this cellular type contributes to tau-induced toxicity ([@B56]). Considering the critical role of P2X7R on the astrocytic function ([@B121]), additional studies to determinate whether astroglial P2X7R is contributing to tau-associated pathology should be done.

A recent study reported that PS2 deficient mice are most sensitive to Aβ-induced neuroinflammation due to the upregulation of P2X7R in both glial and neuronal cells in a transcription factor Sp1 (SP1)-dependent manner ([@B141]). Taking into account that SP1 is a transcription factor promoting P2X7R expression ([@B61]) and that neuroinflammation causes SP1 upregulation via activation of intracellular kinases cascades ([@B30]), it is reasonable to think that dysregulation of SP1 may be the factor causing P2X7R upregulation detected in AD. Supporting the involvement of SP1 in the molecular mechanisms underlying Aβ-induced toxicity in AD, a significant increase in both SP1 messenger and protein levels was found in the cortex of AD patients and in two mouse models of AD, APP/PS1 mice and Tg2576 mice ([@B30]). These mice overexpress human APP containing the Swedish mutation under the control of the hamster prion protein promoter ([@B77]). In this line, it was also reported that SP1 as a transcription factor is able to regulate the expression of both APP and tau proteins ([@B83]; [@B72]). However, the potential role of SP1 as a therapeutic target in AD was put in doubt after the observation that its sustained pharmacological inhibition, induced by a selective SP1 inhibitor (mithramycin), caused a significative memory deficit and increased the Aβ~1--42~ and Aβ~1--40~ ratio ([@B31]). These results indicate that global inhibition of SP1 contributes to neurodegeneration rather than plays a protective role. These side effects could be due to the wide range of different off-target genes regulated by SP1 transcription factor ([@B14]; [@B97]; [@B158]).

P2X7R in Amyloidogenic APP Processing {#S3.SS2}
-------------------------------------

Longitudinal studies combining cognitive assessment, PET analysis, and the measurement of pathognostic molecules from the CSF of eFAD and late-onset AD patients showed an early deposition of Aβ in the precuneus and other cortical areas 10--12 years before first AD symptoms appear ([@B176]). Based on these findings, it is currently accepted that Aβ accumulation represents the initial event triggering the disease. Preceding the onset of cognitive impairment, following the initial Aβ accumulation, a sequential tau accumulation can be observed ([@B122]; [@B10]; [@B51]; [@B64]; [@B67]). However, the existence of cases in which senile plaque burden was detected in brains collected from healthy individuals with no dementia ([@B157]; [@B136]), put in doubt that Aβ is the only factor triggering AD. As described above, although APP protein may be processed by both amyloidogenic and non-amyloidogenic pathways in the CNS ([@B69]), it is postulated that in healthy brains APP is preferably cleaved via the non-amyloidogenic pathway ([@B172]). Nevertheless, deregulation in this balance might favor amyloidogenic processing, leading to Aβ accumulation ([@B164]).

Different studies using both *in vitro* and *in vivo* approaches postulated that P2X7R might be one of the factors controlling APP processing ([@B38]; [@B102]; [@B34]; [@B43]). APP protein can be processed in two different ways. The amyloidogenic pathway is mediated by β- and γ-secretase and results in the generation of extracellular sAPPβ, Aβ-peptides, and the intracellular C-terminal fragment C99. On the other hand, the non-amyloidogenic pathway involves the α-and γ-secretases and results in the generation of an intracellular C-terminal fragment, called C88, extracellular peptides sAPP and the P3 peptides ([@B154]). Preliminary studies, using mouse neuroblastoma cells (N2a) expressing human APP, reported that BzATP-induced P2X7R activation stimulates the release of sAPP in a mitogen-activated protein kinases (MAPK)-dependent manner. This release was inhibited by selective P2X7R knock-down with siRNA and by specific P2X7R antagonists ([@B38]). In a subsequent study, this group reported that Ezrin/Radixin/Moesin (ERM) are required for P2X7R-dependent processing of APP ([@B34]). However, another group, using two different cell lines, found that the inhibition and not the activation of native or overexpressed P2X7R increases α-secretase activity ([@B102]; [@B43]). *In vivo* studies confirmed that pharmacological blockade of P2X7R reduces size and number of hippocampal senile-plaques in 8-months-old J20 mice (PDGF-APPSw,Ind). These mice overexpress human APP with the Swedish (APP KM670/671NL) and Indiana (APP V717F) mutations under the control of platelet-derived growth factor subunit B (PDGFB) promoter ([@B123]). This beneficial effect was GSK3-dependent ([@B43]). To shed light on these contradictory results, a recent study generated P2X7R deficient APP/PS1 mice. APP/PS1 mice express a chimeric mouse/human APP and human PSN1, with the deletion of exon 9 found in eFAD patients, under the mouse prion protein promoter (APP/PSN1/P2X7^--/--^) ([@B84]). Results obtained in this study confirmed that genetic depletion of P2X7R leads to a significant reduction in the number of senile plaques in 10-months-old APP/PS1 mice. This decrease was accompanied by a drastic decreasing in Aβ peptides levels and rescue of the cognitive deficit developed by APP/PS1 mice ([@B109]). All previous data suggest that dysregulation of P2X7R signaling may be one of the factors promoting APP amyloid processing in AD.

P2X7R in Neuroinflammation Associated With AD {#S3.SS3}
---------------------------------------------

It is widely known that accumulation of Aβ in senile plaques initiates the inflammatory process on AD ([@B113]) and favors the activation of the microglial cells around them ([@B155]). In these cells, the P2X7R upregulation suggests its involvement in microglia cells mediated-neuroinflammatory response on AD ([@B135]; [@B116]). In the following sections, we will describe how the upregulation of P2X7R in microglial cells contributes to neuroinflammation and how this impacts on microglial functionality.

### P2X7R in Inflammasome Activation {#S3.SS3.SSS1}

Microglial cells have dual effects on AD progression. On one side, they promote a decrease in A*β* accumulation by stimulating its phagocytosis, clearance, and degradation. On the other side, chronic microglial activation leads to the release of pro-inflammatory cytokines that can contribute to the neuronal loss ([@B182]; [@B183]). This dual effect may be caused by the activation of microglial cells in two subsets that present different molecular phenotype: the classical (M1) or the selective (M2) activated state ([@B32]; [@B169]). M1 state-activated microglia cells promote the release of pro-inflammatory cytokines, playing a pivotal role in the defense against pathogens or tumor cells. M2 state-activated microglia cells secrete anti-inflammatory cytokines promoting tissue repairment ([@B113]; [@B180]; [@B183]). However, this is a simplified classification since and microglia cells may acquire other activation states ([@B142]). At this regard, a recent genome-wide transcriptome analysis of microglia from models of different neurodegenerative disease has allowed to identify a new disease-associated microglia (DAM) phenotype ([@B92]; [@B162]). DAM, in addition, to express genes characteristic in both classical M1 macrophages and classical M2 macrophages, also express others related to the interferon response, stress response, lysosomal function, and lipid metabolism ([@B162]). One of the first molecules directly linked to activation of DAM was TREM2, a single-immunoglobulin-domain-containing macrophage-specific receptor. Interestingly, recent studies have postulated that this protein plays a central role in the onset and the development of AD because microglia surround and enclose neuritic plaques in a TREM2-dependent manner ([@B184]; [@B117]).

Data obtained from studies using lipopolysaccharide (LPS)-induced neuroinflammation animal model has contributed clarify the role of microglial cells in neuroinflammation ([@B16]). LPS activates Toll-like receptor 4 (TLR4) after binding LBP (LPS-binding protein), an intracellular signaling pathway that leads to the activation of nuclear factor NF-kB by a Myeloid differentiation primary response protein MyD88 (MyD88)-dependent mechanism. When activated, NF-kB translocates to the nucleus, binding the DNA, and promoting the transcription of proinflammatory mediators, such as proinflammatory cytokines like pro-interleukin-1 beta (pro-IL1β), pro-interleukin-18 (pro-IL18), and NLRP3 inflammasome ([@B168]; [@B175]). Activation of this intracellular pathway is a priming event. However, to trigger NLRP3 inflammasome, a cytosolic multiprotein oligomer responsible for the activation of inflammatory responses, a subsequent signal causing a decrease K^+^ levels in the cytosolic microenvironment is required to facilitate the oligomerization of NLRP3. Afterward, the inflammasome recruits the apoptosis-associated speck-like protein (ASC) and the procaspase-1 (another apoptosis-related protein), leading to the secretion of IL1β and IL18 ([@B139]; [@B71]). Several studies have shown that ATP, found at high extracellular concentrations following insults ([@B20], [@B21]) or released by Aβ peptide ([@B88]; [@B151]; [@B147]; [@B63]), may be one of the signals promoting NLRP-inflammasome assembling and subsequent IL1β processing ([@B93]; [@B138]; [@B188]). Interestingly, recent studies have reported that NLRP3 activation may also induce tau hyperphosphorylation and aggregation in an IL-1β-dependent manner ([@B81]). Initially, *in vitro* studies using microglial cells isolated from rat brains showed that fibrillar Aβ~1--42~ peptide-induced ATP-release by P2X7R-dependent mechanism ([@B88]). Later, using both *in vitro* and *in vivo* approaches, it was suggested that Aβ-induced microglial activation requires the activation of P2X7R via an autocrine/paracrine stimulatory loop ([@B151]). Additional research revealed that Aβ causes via a P2X7R-dependent mechanism NF-kB activation and NLRP3 inflammasome expression in microglial cells ([@B27]). Since pretreatment of cultured microglial cells with potassium chloride (KCl), avoided microglial NRLP3 activation ([@B66]), it is reasonable to postulate that efflux of K^+^ induced by P2X7R activation is the mechanism by which P2X7R promotes NRLP3 activation in microglial cells. These studies are suggesting that P2X7R/NLRP3/Caspase1 signaling is a crucial pathway in the inflammasome activation once the microglial cell is primed. In accordance with this hypothesis, [@B110] found that upregulation of P2X7R in microglial cells takes place in advanced and late stages of AD, but not in the early stages, when the microglial priming has not yet occurred, and there is a reduced number of senile plaques. In line with this concept, inflammasome activation in APP/PS1 mice occurs in an age- and Aβ deposition-related fashion ([@B73]). Recent studies have also proposed the involvement of P2X7R in the initial microglial priming induced by serum amyloid A (SAA) protein via TLR4 activation ([@B129]; [@B50]). SAA is a high-density apolipoprotein generated in the liver and released to the systemic circulation, where it is mainly found associated with HDL, in response to inflammation, reaching different organs including the brain ([@B59]). In AD patients, SAA co-localized with cerebral amyloid Aβ-peptide deposits ([@B89]) and it is present in high levels in CSF of AD patients ([@B119]). In cortical microglial cells isolated from rat brain, it was reported that SAA causes microglial priming and inflammasome activation in a P2X7R-dependent manner ([@B50]).

As, in recent years, it has been suggested that the control or reduction of the chronic neuroinflammation associated with neurodegenerative diseases may be an efficient therapeutic strategy ([@B11]; [@B144]; [@B169]). Therefore, the regulation of neuroinflammation associated with AD by P2X7R is gaining relevance as a possible remedial to fight these disorders. This affirmation is based on the concept that chronic neuroinflammation may contribute to neurodegeneration by promoting the release of proinflammatory cytokines, increasing the permeability of blood--brain barrier (BBB) favoring the recruitment of systemic immune effectors cells and causing a synaptic dysfunction leading to neuronal loss ([@B132]; [@B169]). In agreement with this, it has been reported that pharmacological blockade or knocking out the P2X7R in different AD mouse models have positive effects by reducing neuroinflammation ([@B146]; [@B25]; [@B109]). Initial studies reported that *in vivo* pharmacological inhibition of P2X7R by Brilliant Blue G (BBG) attenuated inflammatory response and diminished leakiness of BBB induced by intracerebroventricular (i.c.v.) injection of Aβ~1--42~ peptide in rat hippocampus ([@B146]). In accordance, later study revealed that *in vivo* inhibition of P2X7R by i.p. administration of BBG prevented the spatial memory impairment and cognitive deficiency in an AD mouse model ([@B26]). Another study reported that i.c.v. administration of oxidized ATP (o-ATP), a P2X7R antagonist, attenuated microglial activation and neuronal damage induced by i.c.v. administration of LPS ([@B28]). On the other hand, a sustained P2X7R inhibition by BBG did not modify either the number or the morphology of astroglia or microglial cells. Although, the specific treatment, did reduce IL1β secretion and promote the non-amyloidogenic APP processing in the hippocampus of young J20 mice ([@B43]). Moreover, a recent study has reported that APP/PS1/P2X7R deficient mice present smaller cognitive deficit and better synaptic plasticity than APP/PS1 mice. Furthermore, knocking out P2X7R reduces Aβ-induced chemokines release in glial cells, especially C-C motif chemokine 3 (CCL3), which is related to the pathogenic CD8^+^ T-cells recruitment ([@B109]). All these studies suggest that BBB permeable compounds and selective P2X7R antagonists might be considered as good therapeutic drugs to treat chronic neuroinflammation associated with AD.

### P2X7R in Microglial Migration {#S3.SS3.SSS2}

During neuroinflammation, extracellular ATP and other nucleotides seem to act as "find me" and "eat me" signals ([@B41]). This hypothesis is based on the fact that extracellular ATP is capable of inducing morphological changes in microglial cells favoring their rapid migration toward local brain injury ([@B35]). Initial studies indicated that extracellular purines modulate the microglial migration through their specific metabotropic receptors P2Y12, P2Y1, or P2Y6 ([@B80]; [@B37]; [@B13]; [@B94]). However, new findings also suggest the involvement of ionotropic purinergic receptors in this phenomenon ([@B110]). Using *in vitro* and *in vivo* approaches, [@B110] have recently confirmed that ATP-induced P2X7R activation promotes microglial migration. These findings might explain why there is an enrichment on P2X7R positive microglial cells around the senile plaques both in AD mouse models and in postmortem brain samples from AD patients ([@B135]; [@B116]; [@B98]; [@B110]). In this line, it reported that P2X7R upregulation in the microglial cell increases in parallel to the incidence of senile plaques ([@B98]). Moreover, *in vivo* blockade of P2X7R by BBG also caused a reduction of GSK3 activity in P2X7R-expressing microglial cells, by increasing p-GSK3 levels ([@B43]). Other *in vitro* studies using BV-2 mouse microglial cells or brain slices also confirmed that GSK3 inhibitors significantly reduced the migratory capacity of microglial cells ([@B190]). All these findings suggest that P2X7R activation not only promotes NLRP3 inflammasome assembling but also stimulates microglial migration.

### P2X7R in Microglial Phagocytosis {#S3.SS3.SSS3}

Another microglia feature that has been related to purinergic signaling is its phagocytic capacity. First studies suggested that purinergic compounds modulated the phagocytic capacity of microglial cells through the metabotropic P2Y6 receptor ([@B80]). However, recent studies have provided additional data indicating that other purinergic receptors may also regulate this microglial function, as P2X7R. In this line, *in vitro* studies using mouse primary microglial cells isolated from the hippocampus demonstrated that both P2X7R genetic depletion using specific RNAi and its pharmacological inhibition by BBG favors microglial phagocytosis of fibrillar Aβ~1--42~ and decreases IL1β secretion capacity. In this line, the enrichment of the culture medium with IL1β reduced the microglial Aβ~1--42~ phagocytosis ([@B127]). Additional evidence on P2X7R mediated-regulation of microglial phagocytosis has also been provided by later studies ([@B85]; [@B110]). Using both *in vitro* and *in vivo* approaches, it has been found that GSK 1482160A, a selective P2X7R inhibitor, significantly increased the phagocytosis of 2 μm diameter fluorescence microspheres by microglial cells expressing P2X7R ([@B110]). Accordingly, other *in vitro* studies using cultured primary human microglial cells confirmed that P2X7R activation induced by 300 μM Bz-ATP decreased the phagocytic capacity of microglial cells. That effect was prevented when they used the selective P2X7R antagonist 50 μM A438079 but not by the selective P2X4R antagonist Bx430 ([@B85]). In agreement with these findings, ATP induced P2X7R activation causes cytoskeleton changes in microglial, reducing their phagocytic capacity ([@B52]). In this line, and taking into account the important role that microglial phagocytosis plays in the removing of senile plaques, it is to worth highlighting that, both in the hippocampus of J20 mice and in postmortem cortical samples from human AD patients, the majority of microglial cells in contact with senile plaques did not express P2X7R. Furthermore, the percentage of microglia expressing P2X7R inside extracellular Aβ deposits remains constant along the AD progression, in opposition to the rising of the total number of microglial cells ([@B110]). Interestingly, in human microglial cells, BzATP-induced P2X7R activation reduced its phagocytic capacity and produced mature caspase-1 by activating the inflammasome, revealing a close relationship between both events ([@B85]). Supporting this concept, the NLRP3 inflammasome inhibitor, MCC950, stimulates Aβ phagocytosis *in vitro* and reduces the number of senile hippocampal plaques in APP/PS1 mice, causing an improvement in their cognitive function ([@B40]). Indeed, double transgenic mice resulting from the crossbreed of APP/PS1 mice and NLRP3^--/--^ or caspase-1^--/--^ (CASP1) mice exhibited a significant reduction in the loss of spatial memory and an enhanced Aβ clearance, compared with APP/PS1 mice. Furthermore, the NLRP3 inflammasome deficiency promoted the switch of microglial cells to M2 state, resulting in decreased deposition of Aβ in APP/PS1 mice ([@B73]). This evidence strongly suggests that therapeutic strategies focusing either on direct inflammasome inhibition or on avoiding its assembling by blocking P2X7R, might be efficient for reducing neuroinflammation and promoting Aβ phagocytosis in AD.

P2X7R in Oxidative Stress Associated With AD {#S3.SS4}
--------------------------------------------

Oxidative stress is a condition where the generation of reactive oxygen species (ROS) exceeds the capacity of antioxidative mechanisms of the cell ([@B193]). High levels of ROS are commonly detected in the brain of patients suffering from different neurodegenerative diseases, including AD ([@B4]; [@B153]). Although these species cannot trigger the neurodegenerative disease on their own, they might favor its progression by promoting the oxidative damage and interacting with mitochondria ([@B42]). Thereby, accumulation of ROS might cause mitochondrial alterations, resulting in increased ROS production and consequent mitochondrial dysfunction, favoring the disease progression. Accordingly, the content of ATP in the tissue is reduced in parallel to the disease progression in APP/PS1 mice. This fact is suggesting that this decline is caused by mitochondrial dysfunction provoked by ROS accumulation ([@B191]). Moreover, Aβ can lead to ROS production, in particular, hydrogen peroxide (H~2~O~2~), that causes the damage of proteins, lipids, and nucleic acids ([@B47]). Several pieces of evidence point to the fact that P2X7R may be the primary receptor involved in the generation of H~2~O~2~ by activating microglial cells ([@B131]). Stimulation of isolated microglial cells from rat brain with ATP or BzATP, induced O~2~^--^ release in NADPH oxidase activation-dependent mechanism. Furthermore, inhibition of phosphatidylinositol 3 kinase, a kinase involved in GSK-3 signaling, attenuated BzATP-induced H~2~O~2~ release, preventing microglial-induced cortical death ([@B135]). *In vitro* studies reported that fibrillar Aβ~1--42~ causes ROS production generated via P2X7R activation induced by ATP released from rat microglial cells in an autocrine manner ([@B88]; [@B104]). Additional studies revealed that P2X7R positive microglial cells surrounding senile plaques express the catalytic NADPH subunit (gp91^phox^) and produce ROS species in APP/PS1 mice. Hence, P2X7R upregulation in microglial cells may result in excessive ROS production induced by Aβ via P2X7R, which contributes to the synaptic toxicity associated with the early stages of AD ([@B98]). Recently, a study using P2X7R-deficient microglial cell line (N13R) has demonstrated that Aβ-induced mitochondrial toxicity requires P2X7R in microglial cells ([@B27]). In agreement with the antioxidative effect of P2X7R antagonists, *in vivo* administration of selective P2X7R antagonist A438073, avoided ROS production and oxidative DNA damage induced by P2X7R activation in spinal cord dorsal horn neurons ([@B125]).

P2X7R in Synaptic Dysfunction and Cellular Death in AD {#S3.SS5}
------------------------------------------------------

Another major hallmark of AD is the extensive loss of synapses correlating with cognitive impairment ([@B95]). One of the most robust pieces of evidence indicating that Aβ deposits contribute to synaptic loss is the observation that a degree of synaptic loss is more evident in the proximity of the senile plaques ([@B96]). Initial studies postulated that the synaptic loss detected in APP/PS1 mice was due to the dysfunction and collapse of the excitatory synapses. This fact was caused by the interaction of the soluble Aβ peptide oligomers coming from the surrounding plaques with these synaptic contacts ([@B90]). However, the molecular mechanism by which Aβ alters synaptic transmission causing a subsequent synaptic loss remains unclear ([@B19]). One hypothesis is that Aβ may interact directly with neuronal synaptic receptors such as metabotropic glutamate receptor 5 mGluR5 ([@B173]), or α7 nicotine acetylcholine receptor α7nAChR ([@B181]). Others postulate that microglial cells activated by Aβ are responsible for assaulting the synapses ([@B76]). Nevertheless, new evidence suggests that synaptic dysfunction associated with AD may be due to dysregulation of P2X receptors mediated neurotransmission; dysregulation that may be triggered by increased extracellular ATP concentration induced by Aβ ([@B26]; [@B148], [@B147]; [@B63]). Supporting this hypothesis, higher K^+^ depolarization-induced ATP release was found in hippocampal nerve terminals isolated from i.c.v. Aβ~1--42~-treated mice ([@B63]). According to this, pharmacological blockade of P2X7R prevents the increase in the current frequency of the excitatory synapse induced by oligomeric Aβ when binding to excitatory neurons ([@B148], [@B147]). Furthermore, pharmacological inhibition of P2X7R prevented Aβ-induced loss of filopodia and spine density in cultured hippocampal neurons ([@B25]). Other studies have provided additional evidence suggesting that P2X7R-mediated ROS production in Aβ-stimulated microglial is one of the mechanisms explaining oligomeric Aβ-mediated synaptic-toxicity in APP/PS1 mice ([@B98]). In accordance with this toxic effect, BzATP-induced P2X7R activation caused microglia-induced cortical cell death ([@B135]). [@B29] reported similar results, observing that *in vivo* P2X7R blockade by o-ATP reduces the number of positive caspase-3 neurons in LPS-injected brains ([@B28]). In concordance with the involvement of P2X7R in the synaptic-toxicity induced by Aβ, P2X7R deficiency rescued the synaptic alterations and LTP deficits detected in APP/PS1 mice ([@B109]). Interestingly, it was reported that, contrary to what was observed in microglial cells, neuronal P2X7R transcription is reduced in J20 mice both in early and advanced stages. This points to the fact that this phenomenon could be an adaptive physiological response to avoid or at least lessen the neuronal loss associated with AD. However, the loss of this capacity may contribute to the exacerbation of neuronal loss in the late stages of AD ([@B110]).

Induced Pluripotent Stem Cells in AD Research {#S4}
=============================================

The currently available knowledge regarding AD is mostly based on results acquired from post-mortem patient samples or animal models mimicking the disease. However, because human brain tissue is extremely hard to obtain, especially if there is a need for early-onset materials, a need for a human-derived *in vitro* system arose. Thus, the Nobel Prize awarded induced pluripotent stem cell (iPSC) technology that allows the genetic reprogramming of mature somatic cells into pluripotent stem cells (PSCs) ([@B167]) became widely utilized.

The differentiation of cells from patient-specific iPSCs provides valuable insight into specific molecular phenotypes of neurodegenerative diseases ([@B115]) because the cells possess the complete genetic background of the patient. Moreover, healthy individuals' derived iPSCs can be genetically modified to introduce disease-specific genetic patterns ([@B134]).

Many neurodegenerative disease models are available to date. For example, AD patient-derived iPSCs are being used by many research groups ([@B82]; [@B91]; [@B133]; [@B165]; [@B8]; [@B23]).

Focusing on AD research, the use of iPSC-derived cells has helped to discover new pathological mechanisms underlying AD pathology. For instance, describing for the first time an autophagic dysfunction due to lysosomal depletion and suggesting that modifying the lysosomal biogenesis could present a novel therapeutic intervention ([@B99]). Besides, iPSC-derived cells responded very differently to drug treatments than APP-overexpressing cell lines and thus demonstrated that it can be a better option for preclinical screening of compounds ([@B105]). iPSC-models have helped to prove that β-secretase has a higher affinity for neuregulin (NRG1) than for APP, which means that it might be possible to inhibit Aβ production via BACE1 processing without affecting BACE1 interactions with its other substrates ([@B12]). Importantly, iPSC-based systems are suitable for compound screening. A correlation between CSF profiles from patients and their own Aβ secretome in the differentiated neuronal cultures was found, showing the relevance of iPSC derived systems in AD modeling ([@B91]). In AD iPSC-derived neurons, constitutional metabolic changes in ROS production without mitochondrial fission and fusion proteins damage have been described. These findings suggest that increased ROS production might have a more important role in amyloid- and tau-pathology than previously anticipated ([@B15]). Furthermore, findings in these models shown tau protein species propagation patterns where tau oligomers, but not monomers, induced accumulation of pathological, hyperphosphorylated tau in human neurons ([@B174]). Therefore, it is realistic to expect that this technology will provide valuable insights into the P2X7R research field in the near future.

Application of 3D cell cultures will help to model more reliably the brain tissue cell interactions and microenvironment, including gradients of signaling molecules ([@B192]). Particularly for neurodegeneration research, 3D systems promote the formation of specific neuronal cell types with complex interactions and development of AD pathologies, taking into account gradients of signaling molecules such as ATP and the subsequent cellular responses within the tissue ([@B124]).

Concluding Remarks {#S5}
==================

Due to the fact that many anti-amyloid clinical trials have failed, Aβ-directed therapies focusing on the reduction of parenchymal Aβ and amyloid deposits in AD brains have been put in doubt ([@B106]). Many strategies were tested: active and passive immunization, secretase inhibitors or drugs avoiding amyloid aggregation, but none of them was effective in modifying the disease course in symptomatic AD patients ([@B68]). However, there are still ongoing active Phase III clinical trials based on monoclonal antibodies against Aβ, new anti-inflammatory molecules and to induce an active immunization, whose results could be concluded later ([@B106]). As results from studies using animal models, mimicking AD pathology are strongly suggesting that Aβ is the triggering disease factor, perhaps, amyloid-direct therapies would be more useful to treat preclinical cases. Moreover, the vast number of symptomatic AD patients require the urgent development of new therapeutic strategies. In recent years, strategies focused on modulating neuroinflammation, or microglial response have taken strength. So, taking this into account, selective P2X7R antagonists might be considered as potential therapeutic drugs. In addition to reducing the Aβ burden, promoting the non-amyloidogenic APP and processing, P2X7R antagonists have also shown anti-inflammatory, neuroprotective, and antioxidant effects, which might counter the pathological conditions associated with AD. Although human iPSC-based studies have not yet reported on the expression of P2X7R in the in vitro models, either on iPSC-derived neurons or astrocytes, the increasing number of AD patient-derived iPSC disease models will promote the emergence of such investigations toward potential therapeutic targets. Indeed, taking into account the complex pathological state found in AD and other neurodegenerative diseases, nowadays it is postulated that many factors together play a role in facilitating the progressive and detrimental neurodegenerative process. Since major biological systems of the human body are involved---such as the nervous system itself, the immune system, the endocrine system, possibly the digestive system ([@B86]; [@B179]) and perhaps others, currently unknown features and mechanisms, it is extraordinarily challenging to target only one of the systems or pathological processes in the attempt to cure neurodegenerative diseases. Perhaps the time has come to rethink the therapeutic strategies to treat these diseases, in a way where multiple mechanisms could be pharmacologically targeted at the same time, as long as the individual interventions could add up and lead to the elimination of the progression or even the symptoms of dementia. As we discussed in this review, P2X7R may be an excellent target for this multi-target therapy.
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